Mangoceuticals, Inc. - MGRX STOCK NEWS

MangoRx (NASDAQ: MGRX) has initiated efficacy studies on its patented respiratory illness prevention technology. The studies, pre-funded and expected to conclude in early Q3, will be conducted in collaboration with Vipragen Biosciences and IntraMont Technologies. The technology aims to reduce the incidence of respiratory illnesses, including H1N1 variants, Avian Flu, common cold, and Coronavirus.

The composition being tested contains a select tannin (enhanced polyphenol) and zinc gluconate. Previous research at Moscow State University showed a 93% decrease in active virus compared to the control group. The product is anticipated to be available as a lozenge or toothpaste, targeting the global influenza market valued at $8.28 billion in 2023.

Mangoceuticals (NASDAQ: MGRX) CEO Jacob Cohen was recently featured on Benzinga All-Access, discussing the company's strategic direction and future plans. Cohen highlighted MangoRx's focus on developing and marketing men's health products in areas such as erectile dysfunction, hair growth, weight loss, and hormone replacement therapies.

During the interview, Cohen emphasized the company's commitment to innovation and excellence in the health and wellness industry. He also discussed recent developments, expanding product offerings, and plans for global expansion, particularly in emerging markets. Cohen expressed optimism about the significant growth opportunities within the health and wellness sector and MangoRx's position to capitalize on these opportunities.

MangoRx (NASDAQ: MGRX) has secured DEA approval for its proprietary HIPAA-compliant operating system via Surescripts, positioning the company at the forefront of the direct-to-consumer telemedicine market. This authorization allows MangoRx to prescribe controlled medications, including hormone replacement therapies, through the nation's leading health information network.

The approval is expected to drive significant growth by enabling the company to expand its offerings and hyperscale operations. MangoRx's new operating system, developed over nearly a year, aims to revolutionize patient management with features like seamless doctor visits, prescription auto-refills, and personalized healthcare solutions. The company anticipates exponential growth in its subscriber base following this milestone.

MangoRx has appointed Dr. Douglas Christianson, N.D. as Director of Medical Research and Product Innovation. Dr. Christianson will drive new product development, conduct market research, and analyze innovative healthcare treatments for men's health, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies. He will develop and certify custom compound formulations and medical protocols, and collaborate with nationwide doctors for onboarding and training. Dr. Christianson, a specialist in male optimization therapies and regenerative medicine, brings extensive experience and insight into current market trends and progressive medicine. His expertise will help MangoRx expand its product offerings and stay ahead of competitors.

MangoRx (NASDAQ: MGRX) has announced a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) to expand its presence in China, Asia Pacific, and Latin America (excluding Mexico). This collaboration aims to enhance the visibility and adoption of MangoRx's men's health products, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, in these rapidly growing markets. ISFLST will leverage its network in the US, China, and South Korea to introduce MangoRx's products. CEO Jacob Cohen highlighted the substantial market opportunity, citing an estimated 400 million males aged 35 and above in China. Marketing activities have already begun in Beijing and Hangzhou, with further plans for South Korea and Southeast Asia.

MangoRx, a developer of men's health products, announced that its Australian patent application for a new preventive care technology has been accepted. This follows a similar acceptance in Japan. The technology targets respiratory and orally transmitted infections using a formulation with GALALCOOL®️, zinc protoporphyrin IX, and tannins. This patent strengthens their global intellectual property portfolio, especially following MangoRx's recent acquisition of Intramont Technologies' patents. The official patent publication is set for June 6, 2024, with an anticipated deed issuance by September 6, 2024, barring any opposition. This move aligns with MangoRx’s mission to offer advanced health solutions worldwide.

MangoRx, a company specializing in men's health and wellness, has received a Notice of Allowance for its Japanese Patent Application No. 2021-545824. This patent, initially applied for by Intramont Technologies, covers a formulation designed to prevent oral and respiratory infections. The technology includes ingredients like GALALCOOL®️, zinc protoporphyrin IX, and tannins. This follows MangoRx's acquisition of Intramont's global patent portfolio, including U.S. Patent 11,517,523. The patent solidifies MangoRx's intellectual property and paves the way for introducing its products in Japan, aligning with its mission to offer advanced preventive care solutions.

MangoRx has announced the upcoming release of MOJO, a new oral dissolvable tablet aimed at treating low testosterone and male hormone imbalances. The product will combine Enclomiphene Citrate, Pregnenolone, and DHEA, and will be marketed to younger males as a $199 monthly subscription. MOJO is designed to stimulate natural testosterone production and support overall hormonal balance, offering a complementary alternative to MangoRx's existing PRIME Testosterone Replacement Therapy. The launch is scheduled before the end of Q2 2024, with the company aiming to capture a significant share of the growing testosterone replacement therapy market, projected to reach $2.9 billion by 2032.

Mangoceuticals announced the completion of its first batch of Mango ED oral dissolvable tablets (ODTs) for the Mexican and Latin American markets. These tablets, containing Tadalafil, will undergo tests in the U.S. for quality assurance. The next phase includes producing three additional lots for bioequivalence and stability testing in Mexico to meet COFEPRIS standards. This effort is in collaboration with Emifarma. The ED market in Mexico is valued at $216 million annually, growing at 4% per year. MangoRx aims to expand into other LATAM countries post-COFEPRIS certification.